Ginkgo biloba extract alleviates liver fibrosis induced by CCl4 in rats

Liver International

Volumn 25, Issue 6, 2005, Pages 1224-1232

  Ding, Jian ^a   Yu, Jieping ^b   Wang, Chengdang ^a   Hu, Wei ^b   Li, Dan ^a   Luo, Yanjun ^b   Luo, Hesheng ^b   Yu, Honggang ^b  

^a FUJIAN MEDICAL UNIVERSITY   (China)

^b WUHAN UNIVERSITY   (China)

Author keywords

Carbon tetrachloride; Collagen I; Ginkgo biloba extract; Liver fibrosis; Transforming growth factor 1

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; CARBON TETRACHLORIDE; COLLAGEN TYPE 1; GINKGO BILOBA EXTRACT; MALONALDEHYDE; MESSENGER RNA; THIOBARBITURIC ACID; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; GENE EXPRESSION; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; LIVER FIBROSIS; LIVER FUNCTION TEST; MALE; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

ALANINE TRANSAMINASE; ANIMALS; ASPARTATE AMINOTRANSFERASES; CARBON TETRACHLORIDE; COLLAGEN TYPE I; GINKGO BILOBA; GROWTH SUBSTANCES; HEPATOCYTES; IMMUNOHISTOCHEMISTRY; LIVER; LIVER CIRRHOSIS, EXPERIMENTAL; MALE; MALONDIALDEHYDE; PHYTOTHERAPY; PLANT EXTRACTS; RATS; RATS, WISTAR; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

EID: 28944452705     PISSN: 14783223     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2005.01169.x     Document Type: Article

References (33)

1. Hernandez-Munoz R, Diaz-Munoz M, Lopez V, Lopez-Barrera F, Yanez L, Vidrio S, et al. Balance between oxidative damage and proliferative potential in an experimental rat model of CC14-induced cirrhosis: protective role of adenosine administration. Hepatology 1997; 26: 1100-10.
2. Cao Q, Mak K M, Lieber C S. DLPC decreases TGF-beta1-induced collagen mRNA by inhibiting p38 MAPK in hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol 2002; 283: 1051-61.
3. Guo M Z, Li X S, Xu H R, Mei Z C, Shen W, Ye X F. Rhein inhibits liver fibrosis induced by carbon tetrachloride in rats. Acta Pharmacol Sin 2002; 23: 739-44.
4. Parola M, Muraca R, Dianzani I, Barbera G, Leonarduzzi G, Bendinelli P, et al. Vitamin E dietary supplementation inhibits transforming growth factor beta 1 gene expression in the rat liver. FEBS Lett 1992; 308: 267-70.
5. Garg R K, Nag D, Agrawal A. A double blind placebo controlled trial of Ginkgo biloba extract in acute cerebral ischaemia. J Assoc Physicians India 1995; 43: 760-3.
6. Kwon Y S, Ann H S, Nabeshima T, Shin E J, Kim W K, Jhoo J H, et al. Selegiline potentiates the effects of EGb 761 in response to ischemic brain injury. Neurochem Int 2004; 45: 157-70.
7. Gardner C D, Messina M, Lawson L D, Farquhar J W. Soy, garlic, and Ginkgo biloba: their potential role in cardiovascular disease prevention and treatment. Curr Atheroscler Rep 2003; 5: 468-75.
8. Zhou W, Chai H, Lin P H, Lumsden AB, Yao Q, Chen C. Clinical use and molecular mechanisms of action of extract of Ginkgo biloba leaves in cardiovascular diseases. Cardiovasc Drug Rev 2004; 22: 309-19.
9. Friedman S L. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 2000; 275: 2247-50.
10. De Bleser P J, Xu G, Rombouts K, Rogiers V, Geerts A. Glutathione levels discriminate between oxidative stress and transforming growth factor-beta signaling in activated rat hepatic stellate cells. J Biol Chem 1999; 274: 33881-7.
11. BRUNT E M. Grading and staging the histopathological lesions of chronic hepatitis: the Knodell histology activity index and beyond. Hepatology 2000; 31: 241-6.
12. Lee P Y, McCay P B, Hornbrook K R. Evidence for carbon tetrachloride-induced lipid peroxidation in mouse liver. Biochem Pharmacol 1982; 31: 405-9.
13. Tsukamoto H, Matsuoka M, French S W. Experimental models of hepatic fibrosis: a review. Semin Liver Dis 1990; 10: 56-65.
14. McKenna D J, Jones K, Hughes K. Efficacy, safety, and use of Ginkgo biloba in clinical and preclinical applications. Alternative Ther Health Med 2001; 7: 70-86, 88-90.
15. Diamond B J, Shiflett S C, Feiwel N, Matheis R J, Noskin O, Richards J A, et al. Ginkgo biloba extract: mechanisms and clinical indications. Arch Phys Med Rehabil 2000; 81: 668-78.
16. Wu Z, Smith J V, Paramasivam V, Butko P, Khan I, Cypser J R, et al. Ginkgo biloba extract EGb 761 increases stress resistance and extends life span of Caenorhabditis elegans. Cell Mol Biol 2002; 48: 725-31.
17. Gohil K, Packer L. Global gene expression analysis identifies cell and tissue specific actions of Ginkgo biloba extract, EGb 761. Cell Mol Biol 2002; 48: 625-31.
18. Zhang C, Zu J, Shi H, Liu J, Qin C. The effect of Ginkgo biloba extract (EGb 761) on hepatic sinusoidal endothelial cells and hepatic microcirculation in CC14 rats. Am J Clin Med 2004; 32: 21-31.
19. Ozenirler S, Dincer S, Akyol G, Ozogul C, Oz E. The protective effect of Ginkgo biloba extract on CC14-induced hepatic damage. Acta Physiol Hung 1997-1998; 85: 277-85.
20. Li C, Luo J, Li L, Cheng M, Huang N, Liu J, et al. The collagenolytic effects of the traditional Chinese medicine preparation, Han-Dan-Gan-Le, contribute to reversal of chemical-induced liver fibrosis in rats. Life Sci 2003; 72: 1563-71.
21. Tang Y, Lou F, Wang J, Li Y, Zhuang S. Coumaroyl flavonol glycosides from the leaves of Ginkgo biloba. Phytochemistry 2001; 58: 1251-6.
22. Schindowski K, Leutner S, Kressmann S, Eckert A, Muller W E. Age-related increase of oxidative stress-induced apoptosis in mice prevention by Ginkgo biloba extract (EGb761). J Neural Transmission 2001; 108: 969-78.
23. Drewa G, Krzyzynska-Malinowska E, Wozniak A, Protas-Drozd F, Mila-Kierzenkowska C, Rozwodowska M, et al. Activity of superoxide dismutase and catalase and the level of lipid peroxidation products reactive with TBA in patients with psoriasis. Med Sci Monitoring 2002; 8: 338-43.
24. Pell EJ, Schlagnhaufer C D, Arteca R N. Ozone induced oxidative stress: mechanisms of action and reaction. Physiol Plant 1997; 100: 264-73.
25. Bissell D M, Roulot D, George J. Transforming growth factorbeta and the liver. Hepatology 2001; 34: 859-67.
26. Massague J, Chen Y G. Controlling TGF-beta signaling. Genes 2000; 14: 627-44.
27. Piek E, Heldin C H, Ten Dijke P. Specificity, diversity, and regulation in TGF-beta superfamily signaling. FASEB J 1999; 13: 2105-24.
28. Gressner A M, Weiskirchen R, Breitkopf K, Dooley S. Roles of TGF-beta in hepatic fibrosis. Front Biosci 2002; 7: 793-807.
29. Schnabl B, Kweon Y O, Frederick J P, Wang X F, Rippe R A, Brenner D A. The role of Smad3 in mediating mouse hepatic stellate cell activation. Hepatology 2001; 34: 89-100.
30. Dooley S, Hamzavi J, Breitkopf K, Wiercinska E, Said H M, Lorenzen J, et al. Smad7 prevents activation of hepatic stellate cells and liver fibrosis in rats. Gastroenterology 2003; 125: 178-91.
31. Bissell D M. Cell-matrix interaction and hepatic fibrosis. Prog Liver Dis 1990; 9: 143-55.
32. Shek F W, Benyon R C. How can transforming growth factor beta be targeted usefully to combat liver fibrosis? Eur J Gastroenterol Hepatol 2004; 16: 123-6.
33. Wrana J L. Transforming growth factor-beta signaling and cirrhosis. Hepatology 1999; 29: 1909-10.